In this Healio Video Perspective from the Retina Society meeting, Sumit Sharma, MD, of Cole Eye Institute discusses how tyrosine kinase inhibitors differ from other treatment options for retinal diseases.
“The tyrosine kinase inhibitors represent a new mechanism of action where these TKIs — vorolanib, sunitinib and axitinib — actually act intracellularly to act as pan-VEGF, FGF and PDGF inhibitors, where they block all of the receptors for the VEGF family,” he said.
Sharma also summarized key findings from the DAVIO 2 trial investigating EYP-1901 (vorolanib intravitreal